| Summary: | <p>Abstract</p> <p>Background</p> <p>Emerging evidence suggests that <it>ataxia telangiectasia-mutated </it>(<it>ATM</it>) is involved in numerous damage repair signaling pathways and cell-cycle checkpoints. Heterozygous carriers of ATM-mutations have an increased risk for the development of breast cancer. The purpose of this study is to evaluate the association between <it>ATM </it>exon39 5557G > A (D1853N, rs1801516) polymorphism and breast cancer susceptibility with the use of a meta-analysis.</p> <p>Methods</p> <p>By searching PubMed and Embase databases, a total of 9 epidemiological studies with 4,191 cases and 3,780 controls were identified. Crude odds ratios (ORs) and their corresponding 95% confidence intervals (CIs) for <it>ATM </it>D1853N polymorphism and breast cancer risk were calculated using fixed- or random-effects model based on the degree of heterogeneity among studies.</p> <p>Results</p> <p>No significant association between the <it>ATM </it>D1853N polymorphism and breast cancer risk was observed in overall analysis (GA versus GG: OR = 1.18; 95% CI, 0.90-1.53; AA versus GG: OR = 0.77; 95% CI, 0.58-1.03; dominant model: OR = 1.16; 95% CI, 0.89-1.51; and recessive model: OR = 0.78; 95% CI, 0.59-1.04, respectively).</p> <p>Conclusion</p> <p>Our results indicate that <it>ATM </it>D1853N polymorphism is not a risk factor for developing breast cancer.</p>
|
|---|
